Recent Ebola epidemics, the ongoing COVID-19 pandemic, and emerging infectious disease threats have highlighted the importance of global infectious diseases and responses to public health emergencies. Ophthalmologists are essential health care workers who provide urgent and emergent vision care services during outbreaks and address the ocular consequences of epidemic and pandemic infectious diseases. In 2017, the World Health Organization (WHO) identified high priority pathogens likely to cause a future epidemic with the goal of guiding research and development to improve diagnostic tests, vaccines, and medicines. These measures were necessary to better inform and respond to public health emergencies. Given the ocular complications associated with emerging infectious diseases, there is a need to recognize the ophthalmic sequelae for future vision health preparedness for potential future outbreaks. The WHO High Priority pathogens list provides a roadmap for ophthalmologists and subspecialty providers that will guide strategic areas of research for clinical care and preparedness for future pandemic threats. This review summarizes these key viral pathogens, summarizes major systemic disease findings, and delineates relevant ocular complications of the WHO High Priority pathogens list, including Crimean-Congo hemorrhagic fever, Filovirus diseases (Ebola virus disease and Marburg hemorrhagic fever), human Coronaviruses, Lassa Fever, Nipah virus infection, Zika, and Rift Valley fever.

Purpose: This report discusses the case of an 86-year-old man with a full-thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab. Methods: A case report is presented. Results: An 86-year-old man presented with a 5-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After 4 treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention. Conclusions: The patient’s FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. Macular hole formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.

Ophthalmic Surgery, Lasers and Imaging Retina | Howard F. Fine Practical Retina Co-Editor One in a million. Acute retinal necrosis (ARN) — although thankfully rare, with some population-based studies pegging its incidence on the order of one in 1 million — can be a devastating condition. The majority of patients are relatively young and appear immunocompetent and,